Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ceftobiprole medocaril by Basilea Pharmaceutica for Skin And Skin Structure Infections (SSSI): Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Skin And Skin Structure Infections...
Ceftobiprole medocaril by Basilea Pharmaceutica for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections....
Ceftobiprole medocaril by Basilea Pharmaceutica for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections....
Ceftobiprole medocaril by Basilea Pharmaceutica for Sepsis: Likelihood of Approval
Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Sepsis. According to GlobalData, Phase...